Physician profile
Rohit K Suri
NPI 1962488056
$1,814.53
in general payments reported to CMS, 2019-2025
9 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Obesity Medicine (Family Medicine) provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $87.63 · 2021: $287 · 2022: $359 · 2023: $444 · 2024: $150 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,081.73 | 2019-2025 | Wegovy |
| Abbvie INC. | $246.43 | 2022-2023 | Qulipta, Ubrelvy |
| Kvk-Tech, INC. | $159.68 | 2019-2022 | |
| Lilly USA, LLC | $129.89 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Esperion Therapeutics, INC. | $126.47 | 2021 | |
| Boston Scientific Corporation | $26.50 | 2019 | |
| Abbott Laboratories | $20.80 | 2019 | |
| Eisai INC. | $11.86 | 2019 | |
| Endo Pharmaceuticals INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Suri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.